BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
“We are pleased to share long-term efficacy and safety data from APeX-2 as published in JACI: In Practice.
- “We are pleased to share long-term efficacy and safety data from APeX-2 as published in JACI: In Practice.
- These data further illustrate the potential lasting outcomes that can be appreciated by patients who are treated with oral, once-daily ORLADEYO.
- In part 3 of the study (weeks 49-96), all patients (n=81) were treated with open-label ORLADEYO at 150 mg.
- JACI: In Practice is an official journal of the American Academy of Allergy, Asthma, and Immunology (AAAAI).